CY1119941T1 - Σταθερα και διαλυτα αντισωματα - Google Patents

Σταθερα και διαλυτα αντισωματα

Info

Publication number
CY1119941T1
CY1119941T1 CY20181100216T CY181100216T CY1119941T1 CY 1119941 T1 CY1119941 T1 CY 1119941T1 CY 20181100216 T CY20181100216 T CY 20181100216T CY 181100216 T CY181100216 T CY 181100216T CY 1119941 T1 CY1119941 T1 CY 1119941T1
Authority
CY
Cyprus
Prior art keywords
antibodies
tnf
methods
disclosure
stable
Prior art date
Application number
CY20181100216T
Other languages
Greek (el)
English (en)
Inventor
Leonardo Borras
David Urech
Original Assignee
Esbatech - A Novartis Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44897558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119941(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esbatech - A Novartis Company Llc filed Critical Esbatech - A Novartis Company Llc
Publication of CY1119941T1 publication Critical patent/CY1119941T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CY20181100216T 2010-10-22 2018-02-22 Σταθερα και διαλυτα αντισωματα CY1119941T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40579810P 2010-10-22 2010-10-22
US201161484749P 2011-05-11 2011-05-11
PCT/CH2011/000256 WO2012051734A1 (en) 2010-10-22 2011-10-24 Stable and soluble antibodies

Publications (1)

Publication Number Publication Date
CY1119941T1 true CY1119941T1 (el) 2018-12-12

Family

ID=44897558

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100216T CY1119941T1 (el) 2010-10-22 2018-02-22 Σταθερα και διαλυτα αντισωματα

Country Status (21)

Country Link
US (3) US8545849B2 (https=)
EP (2) EP3336105B1 (https=)
JP (4) JP6245985B2 (https=)
KR (4) KR101947520B1 (https=)
CN (2) CN103154033B (https=)
AR (1) AR083495A1 (https=)
AU (1) AU2011318179B2 (https=)
BR (1) BR112013010949B1 (https=)
CA (1) CA2814766C (https=)
CL (2) CL2013001089A1 (https=)
CO (1) CO6741152A2 (https=)
CY (1) CY1119941T1 (https=)
MX (2) MX2013004295A (https=)
PH (1) PH12013500675B1 (https=)
PL (1) PL2630159T3 (https=)
RU (2) RU2558298C2 (https=)
TW (3) TWI702230B (https=)
UA (1) UA111340C2 (https=)
UY (1) UY33679A (https=)
WO (1) WO2012051734A1 (https=)
ZA (1) ZA201302537B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104004094B (zh) * 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
AR083495A1 (es) * 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
MX2014004521A (es) * 2011-10-20 2014-05-28 Esbatech A Novartis Co Llc Anticuerpo estable de union a antigenos multiples.
JP6184982B2 (ja) * 2012-02-02 2017-08-23 エスバテック − ア ノバルティス カンパニー エルエルシー 点眼用抗体含有徐放性製剤
KR102165464B1 (ko) * 2012-07-19 2020-10-14 레드우드 바이오사이언스 인코포레이티드 Cd22에 대해 특이적인 항체 및 이들의 사용 방법
EP2935589A1 (en) 2012-12-18 2015-10-28 Novartis AG Compositions and methods that utilize a peptide tag that binds to hyaluronan
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
AU2015335743B2 (en) 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
AU2016350701B2 (en) 2015-11-02 2021-08-19 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
KR102783230B1 (ko) 2015-11-09 2025-03-19 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd22 항체-메이탄신 콘쥬게이트 및 그것의 사용 방법
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
CN109311976A (zh) * 2016-06-20 2019-02-05 诺华股份有限公司 使用TNFα拮抗剂治疗干眼症的方法
SG10201912565QA (en) 2016-09-29 2020-02-27 Amgen Inc Low-viscosity antigen binding proteins and methods of making them
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
EP3997124A4 (en) * 2019-07-09 2024-01-03 National Institute for Biotechnology in the Negev Ltd. ANTIBODIES WITH REDUCED IMMUNOGENICITY
CN112786101B (zh) * 2019-11-07 2024-11-12 中国农业大学 热稳定性抗体的制备方法
WO2021102131A1 (en) * 2019-11-21 2021-05-27 Brown University Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5644034A (en) 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
NZ241855A (en) 1991-03-07 1994-04-27 Gen Hospital Corp Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5213656A (en) 1991-12-04 1993-05-25 Gerber Scientific Products, Inc. Method of using a web for etching of a surface
FI941169L (fi) * 1992-07-13 1994-05-04 Eukarion Inc Lipidisoitujen proteiinien transvaskulaarinen ja intracellulaarinen antaminen
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
ES2159529T5 (es) 1993-03-05 2011-03-09 Bayer Corporation Anticuerpos monoclonales humanos anti-tnf alfa.
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP0659439B1 (en) 1993-12-24 2001-10-24 MERCK PATENT GmbH Immunoconjugates
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
CA2267620A1 (en) 1996-07-16 1998-01-22 Andreas Pluckthun Immunoglobulin superfamily domains and fragments with increased solubility
US6470213B1 (en) 1999-03-30 2002-10-22 Kenneth A. Alley Implantable medical device
EP2392596A3 (en) 1999-12-28 2013-11-27 ESBATech, an Alcon Biomedical Research Unit LLC Intrabodies with defined framework that is stable in a reducing environment and applications thereof
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
SG97908A1 (en) 2000-08-03 2003-08-20 Inst Data Storage A method and apparatus for load/unload testing of disk drives
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
SI2332989T1 (sl) 2002-05-22 2015-06-30 Esbatech, An Alcon Biomedical Research Unit Llc Imunoglobulinski bralni okvirji, ki kaĺ˝ejo izboljĺ ano stabilnost v intraceliäśnem okolju, in postopki za njihovo identifikacijo
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US7060225B2 (en) 2003-03-20 2006-06-13 Northeastern Ohio Universities College Of Medicine Self-contained assay device for rapid detection of biohazardous agents
DE10314412A1 (de) 2003-03-28 2004-10-14 Genovac Ag Genetische Immunisierung mit multiplen Expressionskonstrukten zur Herstellung von monoklonalen Antikörpern
US20050048578A1 (en) 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
EP1651659A4 (en) 2003-08-07 2008-09-17 Epitomics Inc METHOD FOR HUMANIZATION OF MONOCLONAL RABBIT ANTIBODIES
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
NZ563580A (en) 2005-06-07 2010-09-30 Esbatech An Alcon Biomedical R Stable and soluble antibodies inhibiting TNFaplha
NZ563370A (en) 2005-06-20 2010-10-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
GB0520436D0 (en) 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
WO2007042809A2 (en) 2005-10-11 2007-04-19 Domantis Limited Antibody polypeptide library screening and selected antibody polypeptides
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
KR101516823B1 (ko) * 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
ES2547248T3 (es) 2006-04-28 2015-10-02 Delenex Therapeutics Ag Anticuerpos que se unen al dominio extracelular del receptor Tirosina cinasa ALK
EP1918302A3 (en) 2006-05-18 2009-11-18 AvantGen, Inc. Methods for the identification and the isolation of epitope specific antibodies
ES2567402T3 (es) 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
JP2009542232A (ja) 2006-07-10 2009-12-03 エスバテック・アーゲー 上皮および／または内皮層を通過するｓｃＦｖ抗体
WO2008057240A2 (en) 2006-10-27 2008-05-15 Abbott Biotechnology Ltd. Crystalline anti-htnfalpha antibodies
CA2666709A1 (en) 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
IN2009DN05758A (https=) 2007-03-12 2015-07-24 Esbatech Ag
KR20170036814A (ko) 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
KR101530723B1 (ko) 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
US20090074780A1 (en) * 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
US20090098136A1 (en) * 2007-10-15 2009-04-16 Alcon Research, Ltd. Use of tnf receptor antagonists for treating dry eye
EP2225276B1 (en) * 2007-12-31 2014-04-23 Bayer Intellectual Property GmbH Antibodies to tnf alpha
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
PL3241843T3 (pl) 2008-06-25 2021-12-27 Novartis Ag Optymalizacja rozpuszczalności cząsteczek immunowiążących
MX345039B (es) * 2008-06-25 2017-01-16 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el tnfa.
CN104004094B (zh) 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
WO2010006454A2 (en) 2008-06-30 2010-01-21 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
MX2011000009A (es) 2008-07-10 2011-08-15 Esbatech Alcon Biomed Res Unit Metodos y composiciones para la administracion mejorada de macromoleculas.
US8722860B2 (en) 2009-04-16 2014-05-13 Abbvie Biotherapeutics Inc. Anti-TNF-α antibodies and their uses
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
DE112011102355T5 (de) 2010-07-15 2013-04-25 Oleg Iliich Epshtein Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von funktionellen Erkrankungen oder Zuständen des Gastrointestinaltraktes
AR083495A1 (es) * 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
AR083672A1 (es) 2010-11-02 2013-03-13 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
WO2013063114A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against tnf
AU2012328917B2 (en) 2011-10-24 2017-05-25 Abbvie Inc. Bispecific immunobinders directed against TNF and IL-17

Also Published As

Publication number Publication date
US9598487B2 (en) 2017-03-21
US20120100153A1 (en) 2012-04-26
JP6245985B2 (ja) 2017-12-13
CN103154033A (zh) 2013-06-12
JP2017184770A (ja) 2017-10-12
TWI702230B (zh) 2020-08-21
CL2013001089A1 (es) 2014-03-07
CN108359012B (zh) 2021-12-24
JP7148228B2 (ja) 2022-10-05
TWI652068B (zh) 2019-03-01
US20130344086A1 (en) 2013-12-26
US20160176959A1 (en) 2016-06-23
CO6741152A2 (es) 2013-08-30
KR101947520B1 (ko) 2019-02-14
RU2015119440A3 (https=) 2019-01-28
EP2630159B1 (en) 2017-11-22
ZA201302537B (en) 2014-06-25
RU2558298C2 (ru) 2015-07-27
PH12013500675A1 (https=) 2013-06-10
KR101635917B1 (ko) 2016-07-04
PL2630159T3 (pl) 2018-04-30
JP2015193664A (ja) 2015-11-05
PH12013500675B1 (en) 2017-09-06
CN103154033B (zh) 2018-04-24
TW201630623A (zh) 2016-09-01
CN108359012A (zh) 2018-08-03
AR083495A1 (es) 2013-02-27
EP3336105A1 (en) 2018-06-20
UA111340C2 (uk) 2016-04-25
TW201221142A (en) 2012-06-01
EP3336105B1 (en) 2020-11-04
BR112013010949B1 (pt) 2022-02-01
CL2015002735A1 (es) 2016-03-04
RU2013123266A (ru) 2014-11-27
JP2019054814A (ja) 2019-04-11
JP2013544078A (ja) 2013-12-12
US8545849B2 (en) 2013-10-01
KR20130138806A (ko) 2013-12-19
UY33679A (es) 2012-03-30
EP2630159A1 (en) 2013-08-28
KR20160083970A (ko) 2016-07-12
MX351499B (es) 2017-10-17
CA2814766A1 (en) 2012-04-26
AU2011318179B2 (en) 2014-12-11
TW201920270A (zh) 2019-06-01
RU2015119440A (ru) 2015-11-27
US10570198B2 (en) 2020-02-25
AU2011318179A1 (en) 2013-05-02
CA2814766C (en) 2017-11-28
BR112013010949A2 (https=) 2017-09-05
TWI584816B (zh) 2017-06-01
MX2013004295A (es) 2013-06-05
KR20170020558A (ko) 2017-02-22
WO2012051734A1 (en) 2012-04-26
KR20190016137A (ko) 2019-02-15

Similar Documents

Publication Publication Date Title
CY1119941T1 (el) Σταθερα και διαλυτα αντισωματα
CY1123978T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν ton tnf
CY1123902T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι tου καρκινου του οισοφαγου και αλλων καρκινων
CY1123854T1 (el) Πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του καρκινου του προστατη και αλλων καρκινων
CY1124224T1 (el) Πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια κατα του καρκινου του μαστου και αλλων καρκινων
CY1123435T1 (el) Anti-pd-l1 αντισωματα και χρησεις αυτων
CY1123635T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του καρκινου των ωοθηκων και αλλων καρκινων
CL2021000981A1 (es) Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
MX2017012427A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores.
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
MX2017017145A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra cancer de ovario y otros canceres.
MX2007015280A (es) Anticuerpos estables y solubles que inhiben tnf-alfa.
CY1119925T1 (el) Aνti-cd40 αντισωματα, χρησεις και μεθοδοι
CR20200592A (es) NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA LA LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0295)
MX2018004140A (es) Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer pulmonar microcelular y otros tipos de cancer.
MX2018002480A (es) Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer.
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
MX2018005273A (es) Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de mama y otos tipos de cancer.
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
CY1117922T1 (el) Her2/neu-eiδika αντισωματα και μεθοδοι χρησης αυτων
MX363307B (es) Plataformas para suministro de antigenos.
IN2014CN03936A (https=)
CY1124038T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων και ικριωματων αυτων για χρηση στην ανοσοθεραπεια εναντι του ορθοκολικου καρκινου (crc) και αλλων καρκινων
MX355759B (es) Peptidos topk y vacunas que incluyen los mismos.
AR124242A2 (es) Péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres